Oncology

Researchers estimate a 5-year overall survival rate of 42.9% for patients treated with durvalumab compared with 33.4% for those administered a placebo after chemoradiation therapy.

Jonathan Strosberg, MD, section head of the Neuroendocrine Tumor Program and vice president of Medical Oncology at the Moffitt Cancer Center, discusses some of the adverse events patients experienced during the phase 3 trial assessing lutetium Lu 177 dotatate for midgut neuroendocrine tumors.

Medical oncologist Michael Morris, MD, discussed the newest findings of the phase 3 VISION trial, which is investigating the use of 177Lu-PSMA-617 in patients with advanced prostate cancer.

Jonathan Strosberg, MD, section head of the Neuroendocrine Tumor Program and vice president of Medical Oncology at the Moffitt Cancer Center, discusses the methods used during the phase 3 trial to assess lutetium Lu 177 dotatate for midgut neuroendocrine tumors.

Andrea Apolo, MD, a Lasker clinical research scholar and head of the Bladder Cancer Section at the National Cancer Institute, explained what patients with aRCC who were given either nivolumab plus cabozantinib or sunitinib reported in regard to their quality of life during treatment.

Notably, the investigative treatment avoids many of the severe adverse effects common in traditional therapies.

Bemarituzumab is an investigational, potential first-in-class targeted antibody designed to block specific fibroblast growth factors from binding and activating FGFR2b.

Research has also shown activity with sacituzumab govitecan in subsets of patients with triple-negative breast cancer, such as those with active brain metastases.

The use of 177Lu-PSMA-617 resulted in a 60% reduction in radiographic progression or death among patients with advanced prostate cancer.

In PD-L1-positive patients, tislelizumab improved median overall survival by 3.5 months with a 46% decrease in the risk of death compared with chemotherapy.

Jonathan Strosberg, MD, section head of the Neuroendocrine Tumor Program and vice president of Medical Oncology at the Moffitt Cancer Center, gives an overview of the phase 3 trial assessing lutetium Lu 177 dotatate for midgut neuroendocrine tumors.

New research presented at the American Society of Clinical Oncology 2021 annual meeting has found encouraging results with the use of 177Lu-PSMA-617 in patients with advanced prostate cancer.

Andrea Apolo, MD, a Lasker clinical research scholar and head of the Bladder Cancer Section at the National Cancer Institute, detailed some of the AEs experienced by patients with aRCC who were given either nivolumab plus cabozantinib or sunitinib.

Results from the phase 3 TITAN study shows a combination therapy that includes apalutamide may achieve survival benefit without significant burden of adverse effects.

Andrea Apolo, MD, a Lasker clinical research scholar and head of the Bladder Cancer Section at the National Cancer Institute, explained how the phase 3 CheckMate 9ER trial was conducted in order to assess the outcomes by baseline disease characteristics for patients with aRCC.

Andrea Apolo, MD, a Lasker clinical research scholar and head of the Bladder Cancer Section at the National Cancer Institute, discusses her presentation on nivolumab plus cabozantinib versus sunitinib for aRCC.

Study suggests that 8 out of 10 patients with breast cancer who receive treatment with TARGIT-IORT will not need a long course of post-operative external beam radiotherapy.

Frequent prostate-specific antigen screenings may lower the risk of metastasis at the time of diagnosis and lower mortality risk from prostate cancer among younger African American men.

Rates of death among patients with breast cancer due to any cause were 31% higher in states with Medicaid income eligibility limits no greater than 50% of the federal poverty level.

Lung cancer, the most common cancer type with the highest mortality, can largely be categorized by the genetic mutations that cause it.

This is the first and only oncology immunotherapy to show positive phase 3 results in the adjuvant lung cancer setting.

A recent article from the American Cancer Society reports a mixed picture, with historic lows in smoking prevalence but suboptimal obesity, cancer screening, and HPV vaccination levels.

The legislation would require that patients with cancer have access to oral oncology drugs within 72 hours of having the prescription submitted to the patient’s pharmacy benefits manager.

Incidence rates of early-onset colorectal cancer in the United States have increased from 8.6 to 13.1 per 100,000 between 1992 and 2013, with most of this increase attributable to early-onset cancers of the rectum.

Other HPV-associated cancers were found to have increased over the study period, linking this trend to lack of guidelines and other resources.

Inhibiting Toll-like receptor 4 stopped it from accumulating cisplatin, thereby halting the hearing damage caused by the cancer treatment.